Glioblastoma, Part II: Molecular Targets and Clinical Trials, An Issue of Neurosurgery Clinics of North America, 1st Edition
Author :
Linda M. Liau
Date of Publication: 04/2021
This issue of Neurosurgery Clinics, guest edited by Dr. Linda M. Liau, is dedicated to Glioblastoma: Molecular and Clinical Trials. This issue is one of four selected each year by the series consulting editors, Drs. Russell R. Lonser and Daniel K. Re
...view more
This issue of Neurosurgery Clinics, guest edited by Dr. Linda M. Liau, is dedicated to Glioblastoma: Molecular and Clinical Trials. This issue is one of four selected each year by the series consulting editors, Drs. Russell R. Lonser and Daniel K. Resnick. Topics will include—but are not limited to—Pathology & Molecular Markers, Cellular States & Genetic Diversity in Glioblastoma, Mismatch Repair in Glioblastoma Resistance, Genetic Susceptibility in Brain Cancer, Pediatric Gliomas: Molecular Landscape & Emerging Targets, Molecularly Targeted Clinical Trials, Novel Radiation Sensitizers, Immunotherapy Checkpoint Inhibitors, Brain Tumor Vaccines, CAR T Cells, Oncolytic Virotherapy, Targeting Cancer Stem Cells, Therapeutic Delivery to CNS, Theranostics: Dual Modality PET Tracers, and Neuroimaging & Novel Response Assessments.
This issue of Neurosurgery Clinics, guest edited by Dr. Linda M. Liau, is dedicated to Glioblastoma: Molecular and Clinical Trials. This issue is one of four selected each year by the series consulting editors, Drs. Russell R. Lonser and Daniel K. Resnick. Topics will include—but are not limited to—Pathology & Molecular Markers, Cellular States & Genetic Diversity in Glioblastoma, Mismatch Repair in Glioblastoma Resistance, Genetic Susceptibility in Brain Cancer, Pediatric Gliomas: Molecular Landscape & Emerging Targets, Molecularly Targeted Clinical Trials, Novel Radiation Sensitizers, Immunotherapy Checkpoint Inhibitors, Brain Tumor Vaccines, CAR T Cells, Oncolytic Virotherapy, Targeting Cancer Stem Cells, Therapeutic Delivery to CNS, Theranostics: Dual Modality PET Tracers, and Neuroimaging & Novel Response Assessments.
Author Information
Edited by Linda M. Liau, MD, PhD, MBA, Chair, Department of Neurosurgery
Professor, Department of Neurosurgery, UCLA David Geffen School of Medicine
Director, Brain Tumor Program, UCLA David Geffen School of Medicine
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
https://www.eu.elsevierhealth.com/glioblastoma-part-ii-molecular-targets-and-clinical-trials-an-issue-of-neurosurgery-clinics-of-north-america-9780323813051.html168651Glioblastoma, Part II: Molecular Targets and Clinical Trials, An Issue of Neurosurgery Clinics of North Americahttps://www.eu.elsevierhealth.com/media/catalog/product/https://www.eu.elsevierhealth.com/media/catalog/product/placeholder/default/generic_item_image_123x160_1_1.png91.49121.99EURInStock/Medicine and Surgery/Surgery/Neurosurgery/Medicine and Surgery/Neurosurgery/Medicine and Surgery/Surgery/BooksThis issue of Neurosurgery Clinics, guest edited by Dr. Linda M. Liau, is dedicated to Glioblastoma: Molecular and Clinical Trials. This issue is one of four selected each year by the series consulting editors, Drs. Russell R. Lonser and Daniel K. Resnick. Topics will include—but are not limited to—Pathology & Molecular Markers, Cellular States & Genetic Diversity in Glioblastoma, Mismatch Repair in Glioblastoma Resistance, Genetic Susceptibility in Brain Cancer, Pediatric Gliomas: Molecular Landscape & Emerging Targets, Molecularly Targeted Clinical Trials, Novel Radiation Sensitizers, Immunotherapy Checkpoint Inhibitors, Brain Tumor Vaccines, CAR T Cells, Oncolytic Virotherapy, Targeting Cancer Stem Cells, Therapeutic Delivery to CNS, Theranostics: Dual Modality PET Tracers, and Neuroimaging & Novel Response Assessments. This issue of Neurosurgery Clinics, guest edited by Dr. Linda M. Liau, is dedicated to Glioblastoma: Molecular and Clinical Trials. This issue is one of four selected each year by the series consulting editors, Drs. Russell R. Lonser and Daniel K. Resnick. Topics will include—but are not limited to—Pathology & Molecular Markers, Cellular States & Genetic Diversity in Glioblastoma, Mismatch Repair in Glioblastoma Resistance, Genetic Susceptibility in Brain Cancer, Pediatric Gliomas: Molecular Landscape & Emerging Targets, Molecularly Targeted Clinical Trials, Novel Radiation Sensitizers, Immunotherapy Checkpoint Inhibitors, Brain Tumor Vaccines, CAR T Cells, Oncolytic Virotherapy, Targeting Cancer Stem Cells, Therapeutic Delivery to CNS, Theranostics: Dual Modality PET Tracers, and Neuroimaging & Novel Response Assessments.00add-to-cart97803238130512021ProfessionalEdited by Linda M. Liau, MD, PhD, MBA20211Book178w x 254hElsevier24019 Apr 2021PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 10 DAYSEdited by <STRONG>Linda M. Liau</STRONG>, MD, PhD, MBA, Chair, Department of Neurosurgery
Professor, Department of Neurosurgery, UCLA David Geffen School of Medicine
Director, Brain Tumor Program, UCLA David Geffen School of Medicine
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa MonicaBooksThe Clinics: SurgeryNoNoNoNoPlease SelectPlease SelectPlease Select
